Details of the Drug

General Information of Drug (ID: DMI7JF3)

Drug Name

Lucerastat

Synonyms

141206-42-0; UNII-GVS3YDM418; N-Butyldeoxygalactonojirimycin; GVS3YDM418; CHEMBL1086997; N-(n-Butyl)deoxygalactonojirimycin; (2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol; Lucerastat [INN]; N-Butyl-DGJ; NB-DGJ; N-Bu-DGJ; AC1L9UXN; N- Butyldeoxygalactonojirimycin; SCHEMBL6821044; N-Butyl-deoxy-galactonojirimycin; CDP-923; N-N-Butyl Deoxygalactonojirimycin; OGT-923; DTXSID60161601; MolPort-039-015-418; ZX-AT009021; ZINC13719785; BDBM50312528; N-Butyl-D-galacto-1-deoxynojirimycin; AKOS027384398; NCGC00181326

Indication

Disease Entry	ICD 11	Status	REF
Fabry disease	5C56.01	Phase 3	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C10H21NO4
Canonical SMILES: CCCCN1CC(C(C(C1CO)O)O)O
InChI: 1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9+,10-/m1/s1
InChIKey: UQRORFVVSGFNRO-XFWSIPNHSA-N

Cross-matching ID

PubChem CID: 501391
CAS Number: 141206-42-0
TTD ID: D0RE9C

References

1	ClinicalTrials.gov (NCT03737214) A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease. U.S. National Institutes of Health.